Skip to content

HPLC analysis published for every batchTHC < 0.3%Shipped from France10% off when you sign up

CB-13

CB1 and CB2 agonist made in the laboratory, poorly penetrating the brain. Human data limited to a phase I trial.

FranceNarcotic: named in scheduleInternationalUnscheduled
Level of detail

C₂₆H₂₄O₂

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

Data sheet

Names

IUPAC name
naphthalen-1-yl-(4-pentoxynaphthalen-1-yl)methanone
Other names
CB 13 · CB13 compound · CRA-13 · CRA13 · SAB-378 · NVP-SAB378 · naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone

Identifiers

Formula
C₂₆H₂₄O₂
Molar mass
368.50 g/mol
CAS
432047-72-8
PubChem CID
9799417(new tab)
ChEBI
CHEBI:185985(new tab)
InChIKey
RSUMDJRTAFBISX-UHFFFAOYSA-N

Class

Family
Synthetic cannabinoid (SCRA)

Legal status

France
Narcotic: named in schedule
International
Unscheduled
See the legal framework

Updated on

Receptors and activity

  1. CB1Agonist82 out of 100

    CI50 = 15,0 nM (déplacement de [3H]CP-55940, CB1 humain) ; CE50 = 6,1 nM (inversion de l'AMPc, Dziadulewicz et coll., 2007)

  2. CB2Agonist65 out of 100

    CI50 = 98 nM (déplacement de [3H]CP-55940, CB2 humain) ; CE50 = 27,9 nM (Dziadulewicz et coll., 2007)

Bar length shows the relative strength of the interaction, as an indication.

Subjective signature

Calm
8 out of 100
Relaxation of body and mind; reduced mental noise without marked drowsiness.
Clarity
3 out of 100
Sustained attention and clear thinking; functional lucidity, not euphoria.
High
3 out of 100
Euphoria and sensory intensity; altered perception of time and space.
Appetite
3 out of 100
Stimulation of hunger and of taste appreciation (the “munchies” effect).
Sleep
5 out of 100
Sedative effect: aids sleep onset and the continuity of deep sleep.
Editorial estimate, not clinical.

Pharmacology

CB-13 is a synthetic molecule of the naphthyl diaryl ketone class, described in 2007 by the Novartis Institutes for BioMedical Research (Dziadulewicz et al., 2007). It binds human CB1 and CB2 receptors, with an IC50 of 15.0 nM at CB1 and 98 nM at CB2, and behaves as an agonist in functional tests. In mice, central effects appear only at a dose about ten times the median effective dose on allodynia (Slivicki et al., 2022). A phase I trial with single oral doses, in 63 healthy male volunteers divided into seven cohorts, describes it as reasonably well tolerated, with mild to moderate, dose-dependent adverse effects (Gardin et al., 2009). Repeated doses in mice, by contrast, lead to analgesic tolerance and signs of central nervous system activity (Slivicki et al., 2022). In the sources consulted, no recreational use is documented.

Key sources.

History

Source
Laboratory. No natural occurrence is reported in the sources consulted: the molecule comes from pharmaceutical research, and its documented use is that of a research compound.

Origin (pharmaceutical research → illicit market)

No biosynthetic pathway: CB-13 is not reported in hemp or in any living organism in the sources consulted. It is obtained by fully synthetic means, in the chemical class of naphthyl diaryl ketones. Described here by chemical class only.

References

  1. Dziadulewicz et coll., naphtyl-(4-pentyloxynaphtyl)méthanone, agoniste double CB1/CB2, J Med Chem 2007 (new tab)PMID 17630726
  2. Gardin et coll., pharmacocinétique et tolérance en dose unique chez l'humain, Drug Metab Dispos 2009 (new tab)PMID 19144772
  3. Trevaskis et coll., effet alimentaire et transport lymphatique, Pharm Res 2009 (new tab)PMID 19280324
  4. Cluny et coll., SAB378, agoniste CB1/CB2 périphérique et motilité intestinale, J Pharmacol Exp Ther 2010 (new tab)PMID 20571060
  5. Pryce et coll., agonistes CB1 exclus du système nerveux central et spasticité, FASEB J 2014 (new tab)PMID 24121462
  6. Pryce et Baker, antidote à l'intoxication cannabinoïde et hypothermie induite par CB-13, Br J Pharmacol 2017 (new tab)PMID 28800377
  7. Slivicki et coll., analgésie périphérique de CB-13 et tolérance à doses répétées, Pain 2022 (new tab)PMID 34961756
  8. Ford NC et coll., neurones sensitifs CB1 et analgésie de CB-13, Br J Anaesth 2022 (new tab)PMID 34844727
  9. Ford ZK et coll., CB1 dans les ganglions rachidiens humains et effets de CB13, Front Pain Res 2021 (new tab)PMID 35295508
  10. Hur et coll., potentiel d'abus de AM-1248, CB-13 et PB-22, Biomol Ther 2021 (new tab)PMID 33935046
  11. Ummadisetty et coll., CB13 et douleur après brûlure chez le rat, Br J Pharmacol 2026 (new tab)PMID 41787689
  12. Hassan et coll., métabolites oxydés de CRA13 et analogues, Bioorg Med Chem 2018 (new tab)PMID 30217464
  13. Hassan et coll., jeu de données RMN de métabolites oxydés de CRA13, Data Brief 2018 (new tab)PMID 30364648
  14. Alvarez-Fuentes et coll., dosage RP-HPLC de CB13 en nanoparticules PLGA, ScientificWorldJournal 2012 (new tab)PMID 22792051
  15. ChEMBL, CHEMBL244403 (données d'activité du document CHEMBL1148711) (new tab)
  16. ANSM, liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026 (new tab)
  17. Arrêté du 31 mars 2017 modifiant l'arrêté du 22 février 1990 (Légifrance) (new tab)
  18. INCB, Liste verte 2026 (tableaux de la convention de 1971) (new tab)
  19. PubChem, CID 9799417 (new tab)

Structured data

SMILES
CCCCCOC1=CC=C(C2=CC=CC=C21)C(=O)C3=CC=CC4=CC=CC=C43
InChIKey
RSUMDJRTAFBISX-UHFFFAOYSA-N

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.